AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

Summit Therapeutics NASDAQ:SMMT said on Monday that British drugmaker AstraZeneca LSE:AZN would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.Summit's shares rose over 15% in extended trading following the announcement.Here are some…